Pharmacological management of overactive bladder: A systematic and critical review of published economic evaluations

PharmacoEconomics

Volumn 23, Issue 10, 2005, Pages 995-1006

  Getsios, Denis ^a   El Hadi, Wissam ^b   Caro, Ingrid ^b   Caro, J Jaime ^c,d  

^a Caro Research Institute   (Canada)

^b Caro Research Institute   (Canada)

^c CARO RESEARCH INSTITUTE   (United States)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DARIFENACIN; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; SOLIFENACIN; TOLTERODINE;

CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; ECONOMIC ASPECT; EVALUATION; HUMAN; INCONTINENCE; MICTURITION; OVERACTIVE BLADDER; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYMPTOM; URINARY URGENCY; XEROSTOMIA;

BENZHYDRYL COMPOUNDS; COST OF ILLNESS; CRESOLS; FEMALE; HUMANS; MALE; MANDELIC ACIDS; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; PREVALENCE; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS; UNITED STATES; URINARY INCONTINENCE;

EID: 27744513416     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200523100-00003     Document Type: Review

References (72)

1. Wein AJ, Rovner ES. Definition and epidemiology of overactive bladder. Urology 2002; 60 Suppl. 5A: 7-12
2. Abrams P. Describing bladder storage function: overactive bladder syndrome and detrusor overactivity. Urology 2003; 62 Suppl. 5B: 28-37
3. Rovner ES, Gomes CM, Trigo-Rocha FE, et al. Evaluation and treatment of the overactive bladder. Rev Hosp Clin Fac Med Sao Paulo 2002; 57 (1): 39-48
4. Thomas TM, Plymat KR, Blannin J, et al. Prevalence of urinary incontinence. BMJ 1980; 281: 1243-5
5. Parazzini F, Colli E, Origgi G, et al. Risk factors for urinary incontinence in women. Eur Urol 2000; 37: 637-43
6. Sommer P, Bauer T, Nielsen KK, et al. Voiding patterns and prevalence of incontinence in women: a questionnaire survey. Br J Urol 1990; 66: 12-5
7. O'Brien J, Austin M, Sethi P, et al. Urinary incontinence: prevalence, need for treatment, and effectiveness of intervention by nurse. BMJ 1991; 303: 1308-12
8. Kok ALM, Voorhorst FJ, Burger CW, et al. Urinary and fecal incontinence in the community analysis of a MORI poll. BMJ 1992; 306: 532-4
9. Lagace EA, Hansen W, Hickner JM. Prevalence and severity of urinary incontinence in ambulatory adults: an UPRNet study. J Fam Pract 1993; 36: 610-4
10. Thom D. Variation in estimates of urinary incontinence prevalence in the community: effects of differences in definition, population characteristics, and study type. J Am Geriatr Soc 1998; 46: 473-80
11. Schulman C, Claes H, Matthijs J. Urinary incontinence in Belgium: a population-based epidemiological survey. Eur Urol 1997; 32: 315-20
12. Hergoz AR, Fultz NH. Prevalence and incidence of urinary incontinence in community dwelling populations. J Am Geriatr Soc 1990; 38: 273-81
13. Teleman PM, Lidfeldt J, Nerbrand C, et al. Overactive bladder: prevalence, risk factors and relation to stress incontinence in middle-aged women. BJOG 2004; 111: 600-4
14. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760-6
15. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-36
16. Wein A. Diagnosis and treatment of the overactive bladder. Urology 2003; 62 Suppl. 5B: 20-7
17. Thüroff JW. OAB evidence from the urologist's perspective. Eur Urol Suppl 2003; 2: 10-5
18. Ouslander JG. Management of overactive bladder. N Engl J Med 2004; 350: 786-99
19. Andersson K-E. New pharmacologic targets for the treatment of the overactive bladder: an update. Urology 2004; 63 Suppl. 3A: 32-41
20. Appell RA. The newer antimuscarinic drugs: bladder control with less dry mouth. Cleve Clin J Med 2002; 69 (10): 761-9
21. Cannon TW, Chancellor MB. Pharmacotherapy of the overactive bladder and advances in drug delivery. Clin Obstet Gynecol 2002; 45 (1): 205-17
22. Hashim H, Abrams P. Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. Drugs 2004; 64: 1643-56
23. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study. Mayo Clin Proc 2001; 76: 358-63
24. Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003; 78: 687-95
25. Sussman G, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the Antimuscarinic Clinical Effectiveness Trial (ACET). Curr Med Res Opin 2002; 19: 177-84
26. Staskin R. Methodologic shortcomings in a post-hoc analysis. Curr Urol Rep 2002; 3 (6): 431-3
27. Wagner TH, Hu TW. Economic costs of urinary incontinence in 1995. Urology 1998; 51 (3): 355-61
28. McClish DK, Wyman JF, Sale PG, et al. Use and costs of incontinence pads in female study volunteers. J Wound Ostomy Continence Nurs 1999 Jul; 26: 207-8, 210, 213
29. Wilson L, Brown JS, Shin GP, et al. Annual direct costs of urinary incontinence. Obstet Gynecol 2001; 98: 398-406
30. Zhou Z, Jensen GA. Insurance claim costs for overactive bladder disorder. Drug Benefit Trends 2001; 13: 45-48, 53, 58
31. Langa KM, Fultz NH, Saint S, et al. Informal caregiving time and costs for urinary incontinence in older individuals in the United States. J Am Geriatr Soc 2002; 50: 733-7
32. Hu TW, Wagner TH, Bentkover JD, et al. Estimated economic costs of overactive bladder in the United States. Urology 2003; 61: 1123-8
33. Hu TW, Wagner TH, Bentkover JD, et al. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 2004; 63: 461-5
34. Doran CM, Chiarelli P, Cockburn J. Economic costs of urinary incontinence in community-dwelling Australian women. Med J Aust 2001; 174: 456-8
35. Dowell CJ, Bryant CM, Moore KH, et al. Calculating the direct costs of urinary incontinence: a new test instrument. BJU Int 1999; 83: 596-606
36. Tediosi F, Parazzini F, Bortolotti A, et al. The cost of urinary incontinence in Italian women: a cross-sectional study. Pharmacoeconomics 2000; 17: 71-6
37. Hu TW. The economic impact of urinary incontinence. Clin Geriatr Med 1986; 2: 673-87
38. Fultz NH, Herzog R. Self-reported and emotional impact of urinary incontinence. J Am Geriatr Soc 2001; 49: 892-9
39. Avery JC, Gill TK. The impact of incontinence on health-related QOL in a South Australian population sample. Aust N Z J Public Health 2004; 28: 173-9
40. O'Conor RM, Johannesson M, Hass SL, et al. Urge incontinence: quality of life and patients' valuation of symptom reduction. Pharmacoeconomics 1998; 14: 531-9
41. Kobelt G. Economic considerations and outcome measurement in urge incontinence. Urology 1997; 50 Suppl. 6A: 100-7
42. Hagglund D, Walker-Engstrom ML, Larsson G, et al. Quality of life and seeking help in women with urinary incontinence. Acta Obstet Gynecol Scand 2001; 80: 1051-5
43. Ruff CC, van Rijswijk L, Okoli A. The impact of urinary incontinence in African American women. Ostomy Wound Manage 2002; 48: 52-8
44. Heidrich SM, Wells TJ. Effects of urinary incontinence: Psychological well-being and distress in older community-dwelling women. J Gerontol Nurs 2004; 30 (5): 47-54
45. Chiaffarino F, Parazzini F, Lavezzari M, et al. Impact of urinary incontinence and overactive bladder on quality of life. Eur Urol 2003; 43: 535-8
46. Coyne KS, Zhou Z, Thompson C, et al. The impact on health-related quality of life of stress, urge and mixed urinary incontinence. BJU Int 2003; 92: 731-5
47. van der Vaart CH, de Leeuw JR, Roovers JP, et al. The effect of urinary incontinence and overactive bladder symptoms on quality of life in young women. BJU Int 2002; 90: 544-9
48. Yu HJ, Wong WY, Chen J, et al. Quality of life impact and treatment seeking of Chinese women with urinary incontinence. Qual Life Res 2003; 12: 327-33
49. Lin SY, Dougherty MC. Incontinence impact, symptom distress and treatment-seeking behavior in women with involuntary urine loss in Southern Taiwan. Int J Nurs Stud 2003; 40: 227-34
50. Kobelt G, Jonsson L, Mattiasson A. Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model. Neurourol Urodyn 1998; 17: 599-611
51. Arikian SR, Casciano J, Doyle JJ, et al. A pharmacoeconomic evaluation of two new products for the treatment of overactive bladder. Manag Care Interface 2000; 13: 88-94
52. O'Brien BJ, Goerree R, Bernard L, et al. Cost-effectiveness of tolterodine for patients with urge incontinence who discontinue initial therapy with oxybutynin: a Canadian perspective. Clin Ther 2001; 23: 2038-49
53. Getsios D, Caro JJ, Ishak KJ, et al. Oxybutynin extended release and tolterodine immediate release: a health economic comparison. Clin Drug Invest 2004; 24: 81-8
54. Getsios D, Caro JJ, Ishak KJ, et al. Canadian economic comparison of oxybutynin XL and tolterodine in the treatment of overactive bladder. Clin Ther 2004; 26: 431-8
55. Hughes DA, Dubois D. Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence. Pharmacoeconomics 2004; 22: 1047-59
56. Noe LL, Becker RV, Williamson T, et al. A pharmacoeconomic model comparing two long-acting treatments for overactive bladder. J Manag Care Pharm 2002; 8: 343-52
57. Hall JA, Nelson MA, Meyer JW, et al. Costs and resources associated with the treatment of overactive bladder using retrospective medical care claims data. Manag Care Interface 2001; 14: 69-75
58. Johannesson M, O'Conor RM, Kobelt-Nguyen G, et al. Willingness to pay for reduced incontinence symptoms. Br J Urol 1997; 80: 557-62
59. Turner DA, Shaw C, McGrother CW, et al. The cost of clinically significant urinary storage symptoms for community dwelling adults in the UK. BJU Int 2004; 93: 1246-52
60. Desgagné A, LeLorier J. Incontinence drug utilization patterns in Quebec, Canada. Value Health 1999; 2: 452-8
61. McGhan WF. Cost effectiveness and quality of life considerations in the treatment of patients with overactive bladder. Am J Manag Care 2001; 7 (2 Suppl.): S62-75
62. The Continence Foundation. Making the case for investment in an integrated continence service 2000. The Continence Foundation, London UK [online]. Available from URL: http://www.continence-foundation.org.uk/in-depth/ integrated-continence-service.php [Accessed 2003 Jun 20]
63. Anderson RU, Mobley D, Blank B, et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J Urol 1999; 161: 1809-12
64. Van Kerrebroeck P, Kreder K, Joans U, et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology 2001; 57: 414-21
65. Hay-Smith J, Herbison P, Ellis G, et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2002; (3): CD003781
66. Herbison P, Hay-Smith J, Ellis K, et al. Effectiveness of anti-cholinergic drugs compared with placebo in the treatment of overactive bladder: a systematic review. BMJ 2003; 326: 841-4
67. Noe LL, Becker RV, Chen DM, et al. A straightforward cost-effectiveness analysis of long-acting treatments for overactive bladder: can it be this simple? [abstract]. ISPOR 5th Annual European Congress; 2002 Nov 3-5; Rotterdam, The Netherlands. Value Health 2002; 5 (6): 582-3
68. Becker RV, Noe LL, Chen DM, et al. Evaluating the cost of long acting treatments for overactive bladder [abstract]. ISPOR 5th Annual European Congress; 2002 Nov 3-5; Rotterdam, The Netherlands. Value Health 2002; 5 (6): 582
69. El-Hadi W, Getsios D, Feng W, et al. Ditropan XL provides superior outcomes and lower costs compared to Detrol LA [abstract]. ISPOR 9th Annual International Meeting; 2004 May 16-19; Arlington, USA. Value Health 2004; 7 (3): 363
70. Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 2000; 6 (11 Suppl.): S574-9
71. Holroyd-Leduc JM, Straus SE. Management of urinary incontinence in women: scientific review. JAMA 2004; 91: 986-95
72. Majumdar A, Toozs-Hobson P. Detrusor overactivity. Curr Obstet Gynaecol 2004; 14: 395-404